Electrospray encapsulation of toll-like receptor agonist resiquimod in polymer microparticles for the treatment of visceral leishmaniasis.

@article{Duong2013ElectrosprayEO,
  title={Electrospray encapsulation of toll-like receptor agonist resiquimod in polymer microparticles for the treatment of visceral leishmaniasis.},
  author={Anthony D Duong and Sadhana Sharma and Kevin J. Peine and Gaurav Gupta and Abhay R Satoskar and Eric M Bachelder and Barbra E Wyslouzil and Kristy M. Ainslie},
  journal={Molecular pharmaceutics},
  year={2013},
  volume={10 3},
  pages={1045-55}
}
Leishmaniasis is a disease caused by the intracellular protozoan, Leishmania. A current treatment for cutaneous leishmaniasis involves the delivery of imidazoquinolines via a topical cream. However, there are no parenteral formulations of imidazoquinolines for the most deadly version of the disease, visceral leishmaniasis. This work investigates the use of electrospray to encapsulate the imidazoquinoline adjuvant resiquimod in acid sensitive microparticles composed of acetalated dextran (Ac-DEX… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS